Intravenous immunoglobulin replacement treatment does not alter polymorphonuclear leukocytes function and surface receptors expression in patients with common variable immunodeficiency.
The study of the expression of CD16, CD11b and Siglec 9 receptors and the oxidative burst provides insights on polymorphonuclear leukocytes (PMN) functionality in common variable immunodeficiency (CVID) and on the possible effects of intravenous immunoglobulin (IVIg) infusion. We evaluated in vivo before and soon after IVIg administration the CD16, CD11b and Siglec 9 expression on unstimulated and Escherichia coli-stimulated PMN and the oxidative burst induced by Escherichia coli and PMA. The E. coli stimulation up-regulated CD16 and Siglec 9 expression and it induced a strong CD11b up-regulation at baseline and soon after IVIg. The oxidative burst overlapped that observed in healthy donors when induced by Escherichia coli while it increased when induced by PMA. Soon after IVIg infusion, the oxidative burst decreased only when induced by PMA. Our results showed that the IVIg infusion in vivo had a minimal effect on CVID's PMN.
Department of Molecular Medicine, Sapienza University of Rome, Italy.
Alessandro
A
Prezzo
Department of Molecular Medicine, Sapienza University of Rome, Italy.
Filomena Monica
FM
Cavaliere
Department of Molecular Medicine, Sapienza University of Rome, Italy.
Caterina
C
Bilotta
Department of Paediatrics, Sapienza University of Rome, Italy.
Metello
M
Iacobini
Department of Molecular Medicine, Sapienza University of Rome, Italy. Electronic address: isabella.quinti@uniroma1.it.
Isabella
I
Quinti
D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D039481:CD11b Antigen / Q000378:metabolism; D002478:Cells, Cultured; D017074:Common Variable Immunodeficiency / Q000276:immunology / Q000628:therapy*; D004926:Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000276:immunology*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D018384:Oxidative Stress / Q000187:drug effects; D017452:Receptors, IgG / Q000378:metabolism; D063265:Sialic Acid Binding Immunoglobulin-like Lectins / Q000378:metabolism; D055815:Young Adult
D015703:Antigens, CD; D039481:CD11b Antigen; D016756:Immunoglobulins, Intravenous; D017452:Receptors, IgG; C412227:SIGLEC9 protein, human; D063265:Sialic Acid Binding Immunoglobulin-like Lectins
CD11b; CD16; CVID; IVIg; Oxidative burst; PMN; Siglec 9